These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28529070)

  • 1. Parameters influencing the course of passive drug loading into lipid nanoemulsions.
    Göke K; Bunjes H
    Eur J Pharm Biopharm; 2018 May; 126():123-131. PubMed ID: 28529070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carrier characteristics influence the kinetics of passive drug loading into lipid nanoemulsions.
    Göke K; Bunjes H
    Eur J Pharm Biopharm; 2018 May; 126():132-139. PubMed ID: 28807819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid nanoparticles: drug localization is substance-specific and achievable load depends on the size and physical state of the particles.
    Kupetz E; Bunjes H
    J Control Release; 2014 Sep; 189():54-64. PubMed ID: 24933601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug solubility in lipid nanocarriers: Influence of lipid matrix and available interfacial area.
    Göke K; Bunjes H
    Int J Pharm; 2017 Aug; 529(1-2):617-628. PubMed ID: 28705617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the drug loading capacity of different lipid nanoparticle dispersions by passive drug loading.
    Rosenblatt KM; Bunjes H
    Eur J Pharm Biopharm; 2017 Aug; 117():49-59. PubMed ID: 28315731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug release studies from lipid nanoparticles in physiological media by a new DSC method.
    Roese E; Bunjes H
    J Control Release; 2017 Jun; 256():92-100. PubMed ID: 28450207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fast dissolution of poorly water soluble drugs from fluidized bed coated nanocomposites: Impact of carrier size.
    Azad M; Moreno J; Bilgili E; Davé R
    Int J Pharm; 2016 Nov; 513(1-2):319-331. PubMed ID: 27639622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoclay-lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption.
    Yang L; Shao Y; Han HK
    Int J Nanomedicine; 2016; 11():1067-76. PubMed ID: 27042061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged release from lipid nanoemulsions by modification of drug lipophilicity.
    Baumann N; Baumgarten J; Kunick C; Bunjes H
    J Control Release; 2024 Oct; 374():478-488. PubMed ID: 39151830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: physicochemical and in vitro pharmaceutical investigations.
    Yasmin R; Tan A; Bremmell KE; Prestidge CA
    J Pharm Sci; 2014 Sep; 103(9):2950-2959. PubMed ID: 24585389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenteral formulation of an antileishmanial drug candidate--tackling poor solubility, chemical instability, and polymorphism.
    Kupetz E; Preu L; Kunick C; Bunjes H
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):511-20. PubMed ID: 23454203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of drug solubility and lipid carrier on drug release from lipid nanoparticles for dermal delivery.
    Zoubari G; Staufenbiel S; Volz P; Alexiev U; Bodmeier R
    Eur J Pharm Biopharm; 2017 Jan; 110():39-46. PubMed ID: 27810471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carrier particle design for stabilization and isolation of drug nanoparticles.
    Tierney T; Bodnár K; Rasmuson Å; Hudson S
    Int J Pharm; 2017 Feb; 518(1-2):111-118. PubMed ID: 27884714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability.
    He W; Yang K; Fan L; Lv Y; Jin Z; Zhu S; Qin C; Wang Y; Yin L
    Int J Pharm; 2015 Nov; 495(1):9-18. PubMed ID: 26325310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous production of fenofibrate solid lipid nanoparticles by hot-melt extrusion technology: a systematic study based on a quality by design approach.
    Patil H; Feng X; Ye X; Majumdar S; Repka MA
    AAPS J; 2015 Jan; 17(1):194-205. PubMed ID: 25344439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid lipid nanoparticles for the controlled delivery of poorly water soluble non-steroidal anti-inflammatory drugs.
    Kumar R; Singh A; Garg N; Siril PF
    Ultrason Sonochem; 2018 Jan; 40(Pt A):686-696. PubMed ID: 28946474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel core-shell dual-mesoporous silica nanoparticles for the production of high bioavailable controlled-release fenofibrate tablets.
    Zhao Z; Gao Y; Wu C; Hao Y; Zhao Y; Xu J
    Drug Dev Ind Pharm; 2016; 42(2):199-208. PubMed ID: 26114553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of nanoemulsions and solid lipid nanoparticles by premix membrane emulsification.
    Joseph S; Bunjes H
    J Pharm Sci; 2012 Jul; 101(7):2479-89. PubMed ID: 22527807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat Treatment of Poloxamer-Stabilized Triglyceride Nanodispersions: Effects and Underlying Mechanism.
    Göke K; Roese E; Bunjes H
    Mol Pharm; 2018 Aug; 15(8):3111-3120. PubMed ID: 29989820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.